FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
-
-
-
-
-
-
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
Legend Biotech (LEGN) announces new data evaluating CARVYKTI
-
-
-
-
-
-
-
Barclays shares outlook for Biotech in 2025, names preferred stocks
-
-
-
-
-
-
-
Barclays Reiterates Overweight Rating on Legend Biotech Corp. (LEGN)
-
-
-
-
-
-
-
Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
-
325,857 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

